KOL Insight - Psoriasis

This report examines the evolving landscape of psoriasis treatment, with a focus on the clinical and market impact of leading biologics-including Skyrizi, Tremfya, and Bimzelx-which are projected to dominate the therapeutic pathway over the next five years. It analyses the anticipated influence of icotrokinra on the oral therapy segment, particularly its effect on Otezla's positioning, and evaluates the expanding role of biosimilars such as adalimumab and ustekinumab in first-line management for joint and plaque psoriasis. Gain insights into shifting prescribing patterns, the drivers behind earlier biologic use, and the implications of these developments for future treatment strategies and market dynamics.

Key Questions Answered:

• How are currently approved therapies for psoriasis used and perceived by clinicians?
• How do marketed therapies compare with pipeline treatments in efficacy, safety, and administration?
• Which drug classes are expected to most influence future prescribing trends in psoriasis?
• What impact will biosimilars have on the psoriasis treatment paradigm and patient management?
• Which pipeline products show the most promise for changing the current market landscape?
• Which ongoing or upcoming clinical trials could significantly affect psoriasis treatment strategies?
• How will the treatment landscape evolve for different patient segments and lines of therapy?
• What is the expected role and performance of new oral therapies in psoriasis management?
• What are KOLs' expectations and unmet needs in the psoriasis market?
• How will the introduction of new therapies affect current treatment algorithms and key players?

Key Brands:

Partial List of Participating Experts:

• Clinical Assistant Professor of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
• Assistant Professor of Dermatology; Director, Psoriasis Treatment Program, Department of Dermatology, Yale School of Medicine, New Haven, CT.
• Professor and Chief of Dermatology, University of California Los Angeles, Los Angeles, CA.
• Professor of Dermatology at Hopital Saint-Louis, Paris, France.
• Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
• Professor of Dermatology, Lausanne University Hospital, Lausanne, Switzerland.

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.